<?xml version="1.0" encoding="UTF-8"?>
<p>The inhibitors of integrin α4β1, also known as VLA-4 (Very Late Antigen-4), might serve as useful agents in the treatment of asthma, rheumatoid arthritis, inflammatory bowel disease, multiple sclerosis, Alzheimer’s disease (AD), and stroke [
 <xref rid="B82-antibiotics-10-00092" ref-type="bibr">82</xref>]. In interstitial pneumonia (IP), integrin α4β1 expression level is known to be up regulated by inflammatory cytokines [
 <xref rid="B83-antibiotics-10-00092" ref-type="bibr">83</xref>]. The major cause of death of COVID-19 patients is characterized by respiratory failure due to IP [
 <xref rid="B84-antibiotics-10-00092" ref-type="bibr">84</xref>]. Compounds 
 <bold>37</bold> and 
 <bold>38</bold> (
 <xref rid="antibiotics-10-00092-t004" ref-type="table">Table 4</xref>) were identified as potent antagonists of VLA-4 showing p
 <italic>K</italic>
 <sub>i</sub> values of 7.2 and 9.1, respectively [
 <xref rid="B85-antibiotics-10-00092" ref-type="bibr">85</xref>]. Witherington et al. (2020) studied new diarylureas and found compounds 
 <bold>39</bold> and 
 <bold>40</bold> displaying excellent inhibitory potency (p
 <italic>K</italic>
 <sub>i</sub> = 8.7 and 9.3, respectively) [
 <xref rid="B86-antibiotics-10-00092" ref-type="bibr">86</xref>].
</p>
